Internal Medicine
RSSArticles
-
Liraglutide Injection (Victoza®)
A second human glucagon-like peptide 1 (glp-1) analog/receptor agonist has been approved by the FDA for the treatment of type 2 diabetes mellitus (DM2). -
New Considerations in the Work-up of Patients with Chronic Cough
About a third of patients with sleep apnea have chronic cough. Such patients are more likely to be women and to have heartburn and rhinitis. -
A Guide to CV Guidelines
Guidelines to assess cardiovascular risk are often inconsistent and poorly developed. -
Internal Medicine Alert - Full March 15, 2010 Issue in PDF
-
ECG Review: What Is the Frequency?
The ECG shown above was obtained from a 66-year-old woman with chest discomfort. What is going on in this tracing? -
Clinical Briefs By Louis Kuritzky, MD
The burgeoning population of individuals with type 2 diabetes corresponds to a parallel increase in obesity. -
Aortic Stenosis When to Operate
Even if asymptomatic, early elective aortic valve replacement should be considered for increasingly symptomatic patients with severe aortic valve stenosis because they have a poor prognosis with a high event rate and a risk of rapid functional deterioration, especially if the peak aortic jet velocity is above 5.5 m/sec. -
Infectious Disease Alert April 2010 Issue in PDF
-
Clinical Briefs in Primary Care supplement
-
Updates by Carol Kemper, MD, FACP
Yellow fever vaccine (YFV) is a live, attenuated viral vaccine that is manufactured using a variety of strains of YF virus. Milder side effects of YFV occur in 2%-10% of people (headache, muscle aches, and fever) within 3 to 9 days of vaccination.